- Home
- NXL vs NRSN Comparison
NXL vs NRSN Comparison
Compare NXL & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- NRSN
- Stock Information
- Founded
- NXL 2010
- NRSN 2017
- Country
- NXL United States
- NRSN Israel
- Employees
- NXL N/A
- NRSN N/A
- Industry
- NXL Medical Specialities
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- NRSN Health Care
- Exchange
- NXL Nasdaq
- NRSN Nasdaq
- Market Cap
- NXL 24.2M
- NRSN 26.0M
- IPO Year
- NXL 2022
- NRSN 2021
- Fundamental
- Price
- NXL $1.17
- NRSN $1.05
- Analyst Decision
- NXL Strong Buy
- NRSN Hold
- Analyst Count
- NXL 1
- NRSN 1
- Target Price
- NXL $5.00
- NRSN N/A
- AVG Volume (30 Days)
- NXL 121.2K
- NRSN 111.3K
- Earning Date
- NXL 05-20-2025
- NRSN 06-23-2025
- Dividend Yield
- NXL N/A
- NRSN N/A
- EPS Growth
- NXL N/A
- NRSN N/A
- EPS
- NXL N/A
- NRSN N/A
- Revenue
- NXL $168,721.00
- NRSN N/A
- Revenue This Year
- NXL $79.59
- NRSN N/A
- Revenue Next Year
- NXL $334.65
- NRSN N/A
- P/E Ratio
- NXL N/A
- NRSN N/A
- Revenue Growth
- NXL 52.35
- NRSN N/A
- 52 Week Low
- NXL $0.53
- NRSN $0.51
- 52 Week High
- NXL $4.49
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- NXL 23.87
- NRSN 54.22
- Support Level
- NXL $1.75
- NRSN $0.93
- Resistance Level
- NXL $1.39
- NRSN $1.04
- Average True Range (ATR)
- NXL 0.14
- NRSN 0.07
- MACD
- NXL -0.04
- NRSN 0.01
- Stochastic Oscillator
- NXL 6.63
- NRSN 74.94
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.